
Donald P. Lawrence, MD
Massachusetts General Hospital
Massachusetts General Hospital
Dr. Lawrence’s research focuses on the development of novel therapies for melanoma. He leads numerous melanoma clinical trials within the Dana-Farber/Harvard Cancer Center. He is the principal investigator of two NCI-funded, multicenter clinical trials evaluating targeted therapies in cancers selected by prospective genotypic analysis: an intergroup trial of a c-kit inhibitor for the subset of melanomas that harbor mutations in that gene, and a trial of a MEK inhibitor in cancers other than melanoma with BRAF mutations. Dr. Lawrence also has a research interest in immunotherapy for melanoma.

Donald P. Lawrence, MD
Massachusetts General Hospital